Ultragenyx Pharmaceutical | RARE - Operating Profit

Stock Price
25.00
Daily Change
-0.80 -3.10%
Monthly
1.96%
Yearly
-29.80%
Q2 Forecast
24.50

Ultragenyx Pharmaceutical reported $-216M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Kyowa Hakko Kirin JPY 9.52B 28.83B Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xoma USD -15.64M 5.56M Sep/2024